Cargando…

Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression

Vilazodone is a potent selective serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. To assess the efficacy of vilazodone across a range of symptoms and severities of depression, data from two phase III, 8-week, ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Arif, Sambunaris, Angelo, Edwards, John, Ruth, Adam, Robinson, Donald S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901802/ https://www.ncbi.nlm.nih.gov/pubmed/24247740 http://dx.doi.org/10.1097/YIC.0000000000000016

Ejemplares similares

Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder
por: Thase, Michael E., et al.
Publicado: (2014)

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
por: Zhang, Xiao-Fei, et al.
Publicado: (2015)

Clinical Relevance of Vilazodone Treatment in Patients With Major Depressive Disorder: Categorical Improvement in Symptoms
por: Culpepper, Larry, et al.
Publicado: (2014)

A Review of Vilazodone, Serotonin, and Major Depressive Disorder
por: Pierz, Kerri A., et al.
Publicado: (2014)

The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder
por: Sahli, Zeyad T., et al.
Publicado: (2016)

Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Mathews, Maju, et al.
Publicado: (2015)

Vilazodone for the Treatment of Depression: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
por: Wang, Sheng-Min, et al.
Publicado: (2015)

Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy
por: Hellerstein, David J, et al.
Publicado: (2015)

Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials
por: Shi, Ligen, et al.
Publicado: (2016)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder
por: Durgam, Suresh, et al.
Publicado: (2018)

Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study
por: Gommoll, Carl, et al.
Publicado: (2015)

Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials
por: Kornstein, Susan, et al.
Publicado: (2018)

Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials
por: Durgam, Suresh, et al.
Publicado: (2016)

Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice
por: Chauhan, Mohit, et al.
Publicado: (2022)

Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
por: Singh, Mandeep, et al.
Publicado: (2012)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial
por: Citrome, Leslie, et al.
Publicado: (2015)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022)

A Phase III Prospective Active and Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Major Depressive Disorder
por: Sinha, Shubhadeep, et al.
Publicado: (2021)

Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder
por: Thase, Michael E., et al.
Publicado: (2016)

Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials
por: Sambunaris, Angelo, et al.
Publicado: (2014)

Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone
por: Khan, Arif, et al.
Publicado: (2016)

Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study
por: Kadam, Renuka L., et al.
Publicado: (2020)

Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial
por: Durgam, Suresh, et al.
Publicado: (2018)

Randomized trial of vilazodone versus sertraline in depression: Concerns and comments
por: Praharaj, Samir Kumar
Publicado: (2021)

Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials
por: Thase, Michael E., et al.
Publicado: (2017)

Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial
por: Clayton, Anita H., et al.
Publicado: (2015)

Efficacy of vortioxetine on the physical symptoms of major depressive disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)

A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder
por: Sambunaris, Angelo, et al.
Publicado: (2014)

Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study
por: Wesnes, Keith A., et al.
Publicado: (2017)

A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up
por: Findling, Robert L., et al.
Publicado: (2020)

Symptom severity of depressive symptoms impacts on social cognition performance in current but not remitted major depressive disorder
por: Air, Tracy, et al.
Publicado: (2015)

Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder
por: Freeman, Marlene P., et al.
Publicado: (2016)

A 12-week prospective randomized controlled comparative trial of vilazodone and sertraline in Indian patients with depression
por: Bathla, Manish, et al.
Publicado: (2020)

Patterns of activity correlate with symptom severity in major depressive disorder patients
por: Spulber, S., et al.
Publicado: (2022)

Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity
por: Lyndon, Gavin J., et al.
Publicado: (2019)

Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies
por: Clayton, Anita H, et al.
Publicado: (2016)

The Relationship Between Cognitive Dysfunction and Symptom Dimensions Across Schizophrenia, Bipolar Disorder, and Major Depressive Disorder
por: Zhu, Yue, et al.
Publicado: (2019)

Accuracy of automated classification of major depressive disorder as a function of symptom severity
por: Ramasubbu, Rajamannar, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ad3bu9fvd1kg4h8rp757r1qi5t